Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Enterovirus Infection Clear all

Conditions: Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
Interventions: Hepatitis A & B vaccine, Outreach, AIC, SEP; Biological · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 14 Years to 29 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 84 Days
Enrollment: 1,941 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 26
States / cities: Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more

Conditions: Post-Poliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
Interventions: Sucralfate, Placebo, Acetaminophen, Ibuprofen; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Months to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Enterovirus Infection
Interventions: Placebo, Pleconaril; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 15 Days
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Spinal Cord Injury, Spinal Cord Involvement, Spina Bifida, Transverse Myelitis, Polio and Post-polio Syndrome, Syringomyelia, Spinal Stenosis, Spinal Neoplasms, Spinal Cord Diseases
Interventions: SCI Hard; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years to 29 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Charcot Marie Tooth Disease (CMT), Fascioscapulohumeral Muscular Dystrophy, Inclusion Body Myositis, Mitochondrial Myopathy, Nemaline Myopathy, Centronuclear Myopathy, Postpolio Syndrome, Pompe Disease (Late-onset), Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Spastic Paraplegia, Postural Orthostatic Tachycardia Syndrome (POTS), Progressive Muscular Atrophy
Interventions: Whole-body Electrical Muscle Stimulation Exercise; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Poliomyelitis, Postpoliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1982 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Torrance, California

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Polio
Interventions: dmLT, fIPV; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Diphtheria, Tetanus, Pertussis, Polio, Haemophilus Infection
Interventions: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more

Conditions: Spinal Cord Injuries, Poliomyelitis, Post-polio Syndrome, Arthritis, Lower Motor Neurone Lesion
Interventions: C-brace, Stance control orthosis; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 3,372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 71
States / cities: Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more

Conditions: Diphtheria, Polio, Pertussis
Interventions: DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 36
States / cities: Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more

Conditions: Hepatitis C
Interventions: SOF, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Post-polio Syndrome, Physical Activity, Depression, Pain, Sleep Disorders
Interventions: Glutathione; Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years to 120 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York

Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 1,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 23
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions: artus Influenza A/B RT-PCR Test; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more

Conditions: Uveal Melanoma, Liver Metastases
Interventions: CVA21, Ipilimumab; Biological
Lead sponsor: Viralytics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami Beach, Florida • Boston, Massachusetts

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Search by objective public record fields.

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

Study of Mental Fatigue in Polio Survivors

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Pleconaril Enteroviral Sepsis Syndrome

Clinical Trial of a Serious Game for Individuals With SCI/D

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Study of "Post-Polio Syndrome"

Pilot Study Freeze and Transport Immune Cells

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Safety and Immune Response of Different Pediatric Combination Vaccines.

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Glutathione and Health With Post-Polio Syndrome

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Effects of Aging on Primary and Secondary Vaccine Responses

Collection and Testing of Respiratory Samples

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children